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Summary
Gene dosage tests are very important for the molecular diagnosis of diseases caused 
by either deletion or amplification of a specific DNA region containing certain 
genes. Changes in gene copy number may lead to under- or over expression of genes 
responsible for the disease phenotype. Discovering these defects and understanding 
their biological meaning can lead to improved therapeutic opportunities in cancer.
Fluorescent in situ hybridization (FISH) still remains the gold standard method for 
gene dosage analysis. However have several limitations since locus specific probes are 
expensive, the procedure is significantly time-consuming and tandem microduplica-
tions may be undetected as a result of the limited resolution on metaphase spreads. 
Quantitative Real-time PCR is a rapid assay with results available in 24h, has advan-
tages in terms of sensitivity and specificity. In the present study, we have developed 
an assay using TaqManTM multiplex Real-time PCR for gene dosage analysis of onco-
genes EGFR, ERBB2, AKT2, CMYC, MYCN, MYCL1, PI3KCA and REL in 
human cell lines. This method calculates the copy number of each oncogen and is 
a promising alternative technique to FISH and Southern blot. Therefore, this tech-
nique could be considered as a powerful method gene dosage quantitation in clinical 
and research genetic surveys.
Key words: cancer, oncogenes, gene dosage, real time PCR, TaqMan probes.
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Resumen
Desarrollo y validación de PCR múltiplex con sondas TaqMan 
para la cuantificación de la dosis génica en cáncer
La evaluación de la dosis génica constituye una herramienta importante para el diag-
nóstico molecular de enfermedades causadas tanto por la pérdida o amplificación 
de una región específica de ADN. El cambio en el número de copias génicas, puede 
conllevar a la pérdida o sobreexpresión de los genes responsables de fenotipo de la 
enfermedad. El descubrimiento de estas alteraciones y la comprensión de su signifi-
cado biológico pueden conducir al incremento de las oportunidades terapéuticas en 
cáncer. La hibridación fluorescente in situ (FISH) es el método de referencia para el 
análisis de la dosis génica “amplificación”. Sin embargo, presenta algunas limitaciones 
relacionadas con el costo de las sondas locus específicas; el procedimiento es demo-
rado y las microduplicaciones en tándem podrían no ser detectadas como resultado 
de la limitada resolución de las metafases. En este sentido, la PCR cuantitativa es una 
metodología rápida y tiene ventajas en términos de sensibilidad y especificidad. En el 
presente estudio, se estandarizó la PCR multiplex en tiempo real para el análisis de 
la dosis génica de los oncogenes EGFR, ErbB2, AKT2, cMYC, MYCN, MYCL1, 
PI3KCA y REL en líneas celulares tumorales humanas, como una técnica alternativa 
al FISH para evaluar la dosis génica en muestras clínicas de cáncer. 
Palabras clave: cáncer, oncogenes, dosis génica, PCR en tiempo real, sondas 
TaqMan. 
Introduction
In mammals, genetic alteration in gene copy number by amplification or duplication 
has been defined as one of the common mechanisms that lead to deregulation of gene 
expression and to neoplasic transformation (1-3). The number of copies of a gene per 
haploid genome (gene dose) has been analyzed traditionally by techniques such as 
Southern blot or fluorescent in situ hybridization (FISH). However, these techniques 
may not be appropriate when working with small amounts of starting material (i. e., 
paraffin embedded tissues, free plasma DNA) (9, 10). 
The accurate determination of the number of copies of a gene in the genome (gene dos-
age) is essential for a number of genetic analyses. Quantitative real time PCR (qPCR) 
detection has shown advantages over traditional Southern-blot and FISH techniques. 
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Recently, a real-time PCR assay using a TaqMan probe (a fluorescent DNA probe 
based on the 5’ to 3’ exonuclease activity of the Taq polymerase) has been developed 
for quantitative DNA analysis (6). The oligonucleotide probe, with a reporter fluores-
cent dye attached to its 5' end and a quencher dye attached to its 3’ end, hybridizes to 
the target gene. During PCR amplification, the quencher dye is cleaved by the 5’ nucle-
ase activity of Taq polymerase resulting in the accumulation of reporter fluorescence. 
The release of the fluorescent dye during amplification allows for rapid detection and 
quantification of DNA (14). Compared with other methods the TaqMan real-time 
PCR assay has advantages in terms of sensitivity, rapidity and specificity.
Genetic gains and losses, i. e. changes in gene dosages, are common abnormalities of 
human cancers that regulate the expression of genes and are motive forces for this 
evolution (1). Tumor cells bearing an increasing number of gains and losses succes-
sively emerge and are selected for based on the growth advantage caused by the genetic 
changes. Discovery and functional assessment of gene dosage alterations involved in 
carcinogenesis are therefore essential for understanding the biology of the disease and 
can lead to improved therapeutic opportunities. The purpose of the present work was 
to design qPCR multiplex assay with TaqMan probes detection to determine the gene 
dosage of oncogenes EGFR, ERBB2, AKT2, CMYC, MYCN, MYCL1, PI3KCA and 
REL in tumors human cell lines as molecular markers for cancer. 
Material and methods
Samples and DNA extraction
The gene dosage analysis was performed in cell lines obtained from ATCC (Ameri-
can Type Culture Collection): HEp-2 (human laryngeal carcinoma), PC3 (prostatic 
adenocarcinoma), HepG2 (hepatocellular carcinoma), Hep3B (human hepatoma), 
MCF7 (breast adenocarcinoma), MDA-MB (breast adenocarcinoma), HT29 (col-
orectal adenocarcinoma) and MRC5 (normal Lung Fibroblasts), A549 (Human lung 
adenocarcinoma epithelial cell line), H727 (bronchial carcinoid), H292 (lung, carci-
noma, mucoepidermoid), H520 (lung squamous cancer cell line), H82 (small cell lung 
cancer) and the cell line SPG2 from a Colombian patient with large cell anaplastic carci-
noma. The cells were grown in culture medium supplemented to reach confluence. The 
DNA of the cell lines were obtained by enzymatic digestion with proteinase K (2 mg/
ml), extracted with phenol-chloroform isoamyl alcohol and ethanol precipitation. We 
assessed the quality of the extracted DNA by conventional PCR to amplify a 171 bp 
segment of the B-actin (ACTB) gene and agarose gel electrophoresis.
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TaqMan multiplex PCR assay for Gene Dosage Quantification 
The number of gene copies in each sample was evaluated by real-time multiplex PCR 
using Taqman probes. For this, two PCR mixes were performed to amplify 1. EGFR, 
ERBB2, AKT2; 2. MYC, MYCN, MYCL1 y 3. PI3KCA, REL and ACTB genes.
The gene dosage of each oncogene was determined, utilizing the gene ACTB as refer-
ence, with the double-delta CT relative quantification (2-ΔΔCT) method (6) in duplicate 
assays, using the kit TaqMan® Fast Universal PCR Master Mix in the Applied Biosystem 
7500 instrument. The calculations were made according to manufacturer’s specifica-
tions.
It was confirmed earlier that the efficiencies of the amplifications for each gene were 
similar, using the method published by Kenneth et al. (19).
The reactions were made in a final volume of 25 l, containing: 1x Master mix, 0.04 M 
of each primer and 0.375 M of each probe. The PCR program used was: 95°C x 10 min, 
50 cycles (95°C x 15 sec, 61°C x 1 min). Table 1 shows the sequence of primers and probes 
used. A 2-CT value greater than 2 was considered gene amplification. The change in target 
gene copy number was calculated for each gene and sample using the double delta formula 
(2-ΔΔCt), where CT = (Cttarget – Ct-ACTB) CANCER – (Cttarget – Ct-ACTB) NORMAL. A > 2 2-ΔΔCt 
value was considered a significant gene dose increase (6). The change in gene dosage in 
the cancer cell lines was compared with the gene dosage of normal lung fibroblasts cell 
line (MRC5).
To the left of each probe is mentioned the fluorochrome that was used as the “quencher” 
and the reporter on the right side.
TaqMan multiplex PCR assay for cancer
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Results and discussion
In the present work we have described a Taqman multiplex PCR assay for the quantita-
tive analysis of the gene amplification phenomenon in cancer that allows both highly 
sensitive quantitative measurement of the relative number of oncogene copies in can-
cer cell lines.
First, we demonstrated the feasibility of applying the Taqman multiplex assay by opti-
mizing the gene dosage assays. For this, validation experiments were performed to 
determine the amplification efficiencies of primers and probes of oncogenes reported in 
the Cancer genome project database: EGFR, ERBB2, AKT2, MYC, MYCN, MYCL1, 
PI3KCA and REL with DNA serial dilutions within multiplex PCR. The efficiency 
values were measured using the CT slope method; this method involves generating a 
dilution series of the target template and determining the CT value for each dilution. 
A plot of CT versus log DNA concentration was constructed for each gene in the mul-
tiplex PCR. Efficiency calculation from the slopes of the calibration curve according to 
the equation E = 10 [–1/slope] (15, 16, 17). The slopes of the trend lines were (-3.386), 
(-3.234), (-3.161), (-3,252) for ACTB, MYCN, MYC and MYCL1 genes respectively, 
(Figure 1); (-3.207), (-3,396), (-3.39), (-3.286) for ERBB2, AKT2, EGFR and ACTB 
respectively (Figure 2) , and (-3.266), (-3,162), (-3.293) for ACTB, PI3KCA and REL 
genes respectively (Figure 3).
Simultaneous quantitative real-time PCR was run for the target genes and A. ACTB 
(reference). using various amounts of template DNA per reaction. CT values were 
determined and plotted against log input DNA for both genes. The resulting best fit 
line equations were: y = -3.386x + 36.87, -3.234x + 42.71, -3.161x + 42.94 and y = 
-3.252x + 41.49 for genes, respectively. Best fit line slopes were approximately equal 
with high linear correlation (R2 = 0.983 and 0.984, 0.999 and 0.986). The amplifica-
tion efficiency of the Taqman assays was 2.04, 1.97, 2.03 y 2.07 respectively.
Simultaneous quantitative real-time PCR was run for the target genes and ACTB (ref-
erence) using various amounts of template DNA per reaction. CT values were deter-
mined and plotted against log input DNA for both genes. The resulting best fit line 
equations were: y = -3.207x + 42.61, -3.396x + 38.8, -3.390x + 40.89 and y = -3.286x 
+ 42.95 for the genes, respectively. Best fit line slopes were approximately equal with 
high linear correlation (R2 = 0.998 and 0.986, 0.995 and 0.974). The amplification 
efficiency of the Taqman assays was 2.05, 1.96, 1.97 and 2.01 respectively.
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Figure 1. Validation of real-time PCR assays for analysis of B. MYCN, C. MYC y D. MYCL1 gene 
dosage. 
Simultaneous quantitative real-time PCR was run for the target genes and ACTB 
(reference) using various amounts of template DNA per reaction. CT values were 
determined and plotted against log input DNA for genes. The resulting best fit line 
equations were: y = -3.366x + 43.31, -3.162x + 40.08 and -3.293x + 38.83 and for 
genes, respectively. Best fit line slopes were approximately equal with high linear corre-
lation (R2 = 0.97 and 1, and 0,985). The amplification efficiency of the Taqman assays 
was 1.9, 2.07 and 2.01 respectively.
The reliability of the PCR reaction efficiencies was also assessed by plotting ΔCT val-
ues (Ct target - Ct ACTB) against the amount of input DNA in log scale. Through 
a wide range of template DNA input (6-100 ng), the absolute value of the trend line 
slopes for all genes were ≤ 0.1, which indicated the validity of the relative quantitative 
assay by ΔΔCT method.
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Figure 2. Validation of real-time PCR assays for analysis of A. EBB2, B. AKT2, C. EGFR y D. 
ACTB gene dosage.
We assessed the relative numbers of oncogenes copies gene copy number in relation 
to the copy number of a reference gene B-actin which is assumed to be 1 per haploid 
genome (Multiplex TaqMan assay, relative quantification). Genomic DNA was used 
to adapt and validate the multiplex PCR to measure the relative number of EGFR, 
ERBB2, AKT2, MYC, MYCN, MYCL1, PI3KCA and REL copy number in the 
panel of cancer cell lines.
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Change in PI3KCA gene dosage was observed in 76.9% of cell lines, AKT2 and REL 
in 46.15%; ERBB2 in 23%; MYC, MYCN, MYCL1 and EGFR in 7.69%. With this 
method the cells exhibited a gene dosage of REL from 2 to 13 times; ERBB2 gene from 
2 to 9 times; MYC from 2 to 6 times; MYCN gene dose from 2 to 14; MYCL1 from 2 
to 73617,5; EGFR from 2 to 21 and AKT2 from 2 to 992 (Fig. 4-5, Table 2-3).
Figure 3. Validation of real-time PCR assays for analysis of A. ACTB, B. PI3K y C. REL gene do-
sage.
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Figure 4. Gene dosage (fold change) of oncogenes in cancer cell lines A. PI3KCA and REL B. MYC, 
MYCN and MYCL1 C. AKT2, EGFR and ERBB2. 
TaqMan multiplex PCR assay for cancer
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Figure 5. Gene dosage (fold change) of oncogenes in lung cancer cell lines. A. PI3KCA and REL B. 
MYC, MYCN and MYCL1 C. AKT2, EGFR and ERBB2.
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Table 2. Relative number of oncogene copies in cancer cell lines, as measured with the Taqman 
multiplex PCR assay.
Relative copy number of oncogenes in cancer cell lines
Oncogen / Cancer 
Subtype
HEP2 PC3 HEPG2 HEP3B MCF7 MDAMB HT29
LC PAD HC HP BC BAD CAD
PI3KCA 13.2 7.3 17.7 12.4 14.4 9.8 0.8
REL 1.8 1.2 1.9 0.5 2.1 0.2 2
c-MYC 0 0.5 6.6 0.8 0.7 0 0
MYCN 1.2 0.3 1.2 0.2 1.2 0.15 0.6
MYCL1 0.1 0 0.1 0 0.4 0 0.1
HER2/neu 9.2 0.1 0.2 1 0.2 1 0.1
AKT2 2.4 5.8 8.7 4.8 0.4 1.2 0.1
EGFR 0 0 0 0 0 1 0
Table 3. Relative number of oncogene copies in Lung cancer cell lines, as measured with the Taqman 
multiplex PCR assay.
Oncogen / 
Lung cancer 
Subtype
Relative copy number of oncogenes in lung cancer cell lines
A549 H727 H292 H520 H82 SPG2
AD BC MC SQ SCLC LCC
PI3KCA 7.4 4.8 13.5 1.4 0.3 283.3
REL 1.3 13.7 3.6 7.8 2.6 0.02
MYC 0.2 0 1 1 0 0
MYCN 0.1 0.8 0.3 0.1 0.3 14.2
MYCL1 0.3 0 0.2 0 0 73617.5
HER2/neu 0.1 1.5 4 2.2 1.2 0
AKT2 1.0 4.8 0 26.4 29.8 992.6
EGFR 0.4 0.1 0.4 1.5 0 20.9
During carcinogenesis, genetic and epigenetic alterations drive the evolution of tu-
mor towards increased malignancy and treatment resistance. The changes enable tumor 
cells to overcome microenvironmental constraints, sustain proliferation, and invade 
adjacent tissues and distinct organs (13). Gene dosage alterations like gains and losses 
regulate the expression of genes and are motive forces for this evolution (8, 14). Tumor 
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cells bearing an increasing number of gains and losses successively emerge and are se-
lected for based on the growth advantage caused by the genetic changes. Discovery and 
functional assessment of gene dosage alterations involved in carcinogenesis are there-
fore essential for understanding the biology of the disease. 
The AKT2 gene is a serine/threonine kinase key intermediate of signaling pathways 
that regulate cellular processes controlling cell size/growth, proliferation, survival, glu-
cose metabolism, genome stability, and neo-vascularization (2). The gene was shown 
to be amplified and overexpressed in 2 of 8 ovarian carcinoma cell lines and 2 of 15 
primary ovarian tumors (8), and breast carcinomas (3). Overexpression contributes to 
the malignant phenotype of a subset of human pancreatic ductal cancers. In this study, the 
Hep2 cell lines showed an increase in AKT2 gene copy to 2,4; PC3 cell line of 5,8; 
HepG2 cell line of 8,7; Hep3B of 4,8: H727 4,8; H520 of 26,4; H82 of 29,8; and 
SPG2 cell line 992,6 (Table 2 and 3).
The PI3K/Akt signaling network is crucial to widely divergent physiological processes 
that include cell cycle progression, differentiation, transcription, translation and apop-
tosis (4, 12). It has been reported that the activated PI3K/Akt pathway provides major 
survival signals to prostate and many other cancer cells (7). Inhibition of Akt activity 
stimulates apoptosis in a wide range of mammalian cells (24). Therefore, the PI3K/
Akt pathway is an attractive target for the development of of novel therapeutic strate-
gies in patients with various tumor types. In this study, PI3KCA gene gain copies in 
the cell lines HEP2 (13,2), PC3 (7,3), HEPG2 (17,7), HEP3B (12,4), MCF7 (14,4), 
MDAMB (9,8), A549 (7,4), H727 (4,8), H292 (13,5) and SPG2 (283,3).
While REL has mostly been implicated in lymphoid tumors, a small scale of human 
non-small cell lung carcinomas (NSCLC) revealed elevated REL expression (25). 
Thus, the association of c-rel with human cancers may not be limited to lymphoid cells 
and a comprehensive analysis of c-rel in solid tumors may be particularly informative. 
Rel was amplified in the cell line of breast cancer MCF7 (2,1) and the lung cancer cell 
lines H727 (13,7), H292 (3,6), H520 (7,8) and H82 (2,16). 
EGFR is a 170 kDa receptor tyrosine kinase (RTK) belonging to the ErbB receptor 
family. Upon EGF binding, EGFR dimerizes and activates downstream intracellular 
signal cascades, including Ras / Raf, JAK-STAT and phosphatidyl inositol 3-kinase 
(PIK3CA) / Akt; this results in the modulation of genes involved in cell prolifera-
tion, metastasis, angiogenesis and inhibition of apoptosis (11, 27). Several groups have 
reported that high polysomies and EGFR gene amplification predict favorable treat-
ment response to TKI correlating with increased survival rate. EGFR gene amplifica-
tion leads to protein over-expression and has been correlated with poor prognosis (28). 
In this study only the cell line obtained from a Colombian lung cancer patient, SPG2, 
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showed amplification of EGFR gene with 20.9 copies. EGFR gene copy number is a 
parameter frequently considered to personalize the treatment because it is frequently 
determined of the efficacy of some drugs used in chemotherapy (29). 
The HER2/neu protooncogene is located on the long arm of chromosome 17 (17q21), 
encoding for a transmembranal glycoprotein (p185neu) with intrinsic tyrosine kinase 
activity and marked sequence homology with the epidermal growth factor receptor 
(EGFR). Dimerization of HER2/neu with an activated EGFR molecule leads to the 
activation of a signal transduction cascade with subsequent increase in cell prolifera-
tion, angiogenesis, and metastatic potential, as well as a decrease in apoptosis. Ampli-
fication and/or over-expression of this gene has been reported in numerous cancers, 
including breast and ovarian tumors. In this study amplification of Her2/neu gene was 
observed in the cell lines HEP2 (9.2 copies), H292 (4 copies) and H520 cell line with 
2.2 copies. The cell lines from breast carcinoma MCF7 and MDAMB were no ampli-
fied in this study as reported by (17).
The human MYC family of proto-oncogenes is among the most studied genes in can-
cer (31). Amplification of MYCN has emerged as among the clearest genetic indica-
tors of high-risk, aggressive disease (5, 33). MYC family members (c-MYC, MYC and 
MYCL1) show differential expression in normal tissues. Amplification of the proto-
oncogene MYCN occurs in ~25% of tumors and is the best characterized genetic-risk 
factor for high-risk chemotherapy-refractory disease (32, 33, and 34). In this study 
the gene dosage of c–MYC gene occurred in the hepatocellular carcinoma cell line 
HEPG2 with 6.6 copies, as reported in the literature the expression of the proto-onco-
gene c-myc has been implicated in liver regeneration and hepatocarcinogenesis and the 
amplification is an indicator of malignant potential and poor prognosis in hepatocel-
lular carcinoma (18).
The MYCN and MYCL1 genes were amplified in the Colombian patients cell line 
SPG2 with 14, 2 and 73617,5 copies respectively. MYCN was originally identified 
by oncogene expression profiling of human neuroblastoma cells (36). These surveys 
quickly established that, with few exceptions, cultured neuroblastoma cell lines carry 
the gene MYCN in amplified form. At the same time, neuroblastoma tumors were also 
found to carry amplified MYCN. The initial surveys suggested that MYCN amplifica-
tion was specific for neuroblastoma. It turned out later that MYCN amplification can 
be seen in small cell lung cancer, retinoblastoma, malignant gliomas, and peripheral 
neuroectodermal tumors, although at a much lower incidence. As a common feature, 
all these tumors have neural qualities. Amplification values usually range between 50- 
and 100-fold, although much higher values have been reported in some cases. There is 
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little data about c-myc DNA amplification in histological types of lung cancer other 
than small cell carcinoma. 
This method calculates the copy number of each oncogen and is a promising alterna-
tive technique to FISH and Southern blot. Therefore, this technique should be con-
sidered as a powerful method gene dosage quantitation in clinical and research genetic 
surveys.
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